Navigation Links
$2.5 Million Gift Aims to Help Children Survive and Thrive
Date:3/24/2010

Dr. David Wessel Named IKARIA® Distinguished Professor of Critical Care Medicine at Children’s National Medical Center

Washington, DC (Vocus) March 24, 2010 -- On Tuesday Children’s National Medical Center appointed David L. Wessel, MD, as the first IKARIA® Distinguished Professor of Critical Care Medicine. Dr. Wessel is the division chief and senior vice president of hospital-based specialties and is internationally known for his pioneering work in caring for infants with heart disease.

The $2.5 million endowment was created by IKARIA, a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients.

“The dedication of the health care professionals who work in the critical care environment is our constant inspiration,” said Daniel Tassé, chairman and chief executive officer of IKARIA. “Caring for critically ill patients demands commitment, passion and perseverance, and we are honored to have the opportunity to recognize the outstanding work of Dr. David Wessel, who has demonstrated extraordinary achievement in this area.”

Edwin K. Zechman Jr., president and CEO of Children’s National, said, “We are grateful for IKARIA’s generosity and commitment to improving the care of our most vulnerable patients. This partnership will be life-changing – and life-saving – for so many.”

Dr. Wessel said, “We are convinced that refining critical care treatments will improve long-term physical and developmental outcomes for our young patients. At Children’s National Medical Center, our goal is for children to not only survive, but thrive.”

Educated and trained in medicine at Oxford, Yale and Harvard, Dr. Wessel joined Children’s National Medical Center in July 2007. Prior to joining Children’s National he was professor of pediatrics at Harvard Medical School and senior associate in cardiology and anesthesia at Children’s Hospital Boston. He is board certified in anesthesiology, pediatrics, pediatric cardiology and pediatric critical care medicine.

An experienced scientist and clinical researcher with over 100 peer-reviewed publications, Dr. Wessel has made seminal contributions to the field of critical care medicine. Widely viewed as the “father of pediatric cardiac intensive care,” he has trained a vast number of practicing clinical leaders in the field. Dr. Wessel has also been listed as one of the “Best Doctors in America” continuously since the inception of the ranking.

Dr. Wessel is married and has four children.

Contact Stacy Williams, 301-565-8523, stwillia(at)cnmc(dot)org

About Children’s National Medical Center
Children's National Medical Center, located in Washington, DC, is a proven leader in the development of innovative new treatments for childhood illness and injury. Children’s has been serving the nation's children for more than 135 years. Children’s National is ranked among the best pediatric hospitals in America by US News & World Report and the Leapfrog Group. For more information, visit www.ChildrensNational.org.

About IKARIA Holdings, Inc.
Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company’s lead product, INOMAX® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOMAX and hydrogen sulfide. Ikaria acquired the North American rights to terlipressin, a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide licenses to BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction, and to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute lung and kidney injury. Ikaria is headquartered in Clinton, N.J., with research facilities in Seattle, Wash., and Madison, Wisc., and a manufacturing facility in Port Allen, La. For more information, visit www.ikaria.com.

###

Read the full story at http://www.prweb.com/releases/childrens-national/IKARIA-Holdings/prweb3773644.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. GSK Joins Global Vaccine Alliance to Help Prevent Millions of Children from Contracting Pneumococcal Disease in the Worlds Poorest Countries
2. New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant
3. Wireless LAN Innovator Aerohive Secures $23.5 Million Series C Investment
4. Bloomberg School of Public Health awarded $15 million for laboratory renovation and modernization
5. Massage Envy Performs 20 Millionth Massage
6. PROLOR Biotech Announces Sale of $24.4 Million of Common Stock
7. National Center for Policy Analysis and Salem Radio Network Deliver One Million Emails to Congress to Stop ObamaCare
8. Democracy on Trial: SEIUs $25 Million Lawsuit Against Union Reformers Goes to Court Monday
9. 27th Annual Shamrocks Against Dystrophy Sets $20 Million Fundraising Record
10. Non-Melanoma Skin Cancers in the Millions and Rising
11. Online Medical Supplies Superstore Ships 1 Millionth Order
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
$2.5 Million Gift Aims to Help Children Survive and Thrive
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology: